L
Lutonix
Health Tech & Medtech · Maple Grove, United States · Founded 2007
New drug-coated balloon catheter that delivers paclitaxel to the arterial wall in a single, short inflation MoreLess
Lutonix specializes in the development and commercialization of drug-coated balloons (DCBs) for angioplasty procedures. The company operates in the medical device market, primarily serving healthcare providers and medical institutions that perform vascular interventions. Lutonix's core product, the Lutonix DCB, is the first and only DCB to receive FDA approval for use in long lesions up to 300mm and dysfunctional arteriovenous (AV) fistulae. This product is designed to improve patient outcomes by reducing the need for repeat interventions compared to standard angioplasty.
Lutonix generates revenue through the sale of its DCBs, which are available in various sizes and configurations to meet the needs of different vascular conditions. The company also participates in clinical trials and maintains a global registry to provide evidence of the efficacy and safety of its products. By focusing on innovation and regulatory compliance, Lutonix aims to maintain its leadership position in the DCB market.
Keywords: drug-coated balloons, angioplasty, FDA-approved, long lesions, AV fistulae, vascular interventions, medical devices, clinical trials, global registry, healthcare providers.
Company overview
Lutonix company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2007
- Headquarters
- Maple Grove, United States
- Employees
- 10
- Open positions
- None listed
- Dealroom signal
- 59.1
Valuation & funding
Lutonix funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Dec 2011 | $225M | $225M | C. R. Bard | — |
| SERIES C✓Equity / VC | Dec 2010 | $10M | $40M | Undisclosed | — |
| SERIES B✓Equity / VC | Oct 2008 | $20M | $80M | Versant Ventures | — |
| SERIES A✓Equity / VC | Apr 2007 | $5M | $20M | Undisclosed | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 10 |
| 2025 | 10 |
| 2024 | 10 |
| 2023 | 10 |
| 2022 | 10 |
| 2021 | 12 |
| 2020 | 11 |
Growth signals
Lutonix website traffic
Latest recorded traffic for Lutonix is 0 monthly website visits. Lutonix's team grew 0% over the past year.
Comparisons
Lutonix compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Lutonix's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Lutonix has talent and traffic
In the news
Latest news about Lutonix
Recent press, funding announcements, and product moves mentioning Lutonix — open to read from the original sources.
Market sentiment
What the market is saying about Lutonix
An AI-synthesized read of the highest-engagement posts about Lutonix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lutonix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.